Mark Weiser, MD
Sheba Medical Center
6
6
1
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+2 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Elliot Stein, Ph.D.
National Institute on Drug Abuse (NIDA)
Shared therapeutic areas:
Olivier Beauchet, MD
Jewish General Hospital
Shared therapeutic areas:
Sanjeev Pathak, MD
Alkermes, Inc.
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Ebru Calik Kutukcu, PhD
Hacettepe University
Shared therapeutic areas:
Jean-Olivier ARNAUD, Director
Assistance Publique Hôpitaux de Marseille
Shared therapeutic areas:
Urielle Desalbres
Assistance Publique Hôpitaux de Marseille
Shared therapeutic areas:
Nobuhito Sanada
Otsuka Pharmaceutical Co., Ltd.
Shared therapeutic areas:
Nieto Luis, Master
Site Coordinator of United Medical Group located in Miami
Shared therapeutic areas:
Imran Amjad, Phd
Riphah International University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Cognitive Impairments in Psychotic Disorders
Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia
Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia
Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder
Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
Administrating Oxytocin to Treat Treatment Schizophrenia and Schizo-affective Patients
All 6 trials loaded